ifosfamide has been researched along with Leucocythaemia in 26 studies
Excerpt | Relevance | Reference |
---|---|---|
"This article gives highlights of ongoing pediatric solid tumor and leukemia trials in the United States that use ifosfamide in combination with mesna." | 4.79 | Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. ( Pratt, CB, 1996) |
" 4-Hydroperoxyifosfamide appeared to be less cytotoxic against the leukemia cells than 4-hydroperoxycyclophosphamide." | 3.85 | Comparison of ( Blicharski, K; Fedoročko, P; Mazur, L; Mikeš, J; Niemeyer, U; Opydo-Chanek, M; Śladowska, K, 2017) |
"Poor-risk solid tumors were treated with four courses of cyclophosphamide (4,200 mg/m2)/ doxorubicin (75 mg/m2), and three courses of ifosfamide (9,000 mg/m2)/etoposide (500 mg/m2)." | 2.69 | High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. ( Bajorin, D; Cheung, NK; Heller, G; Kramer, K; Kushner, BH; Meyers, PA; Polyak, T; Wollner, N, 1998) |
"Seven of the 15 patients with malignant lymphoma responded." | 2.64 | Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. ( Bodey, GP; Freireich, EJ; Keating, MJ; McCredie, KB; Rodriguez, V; Valdivieso, M, 1978) |
"Etoposide has also been tested in a wide range of combination regimens, but for many of these combinations, relatively few patients are included, and some combinations have only been tested in patients who have undergone autologous transplants." | 2.48 | High-dose etoposide in allogeneic stem cell transplantation. ( Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH, 2012) |
" The authors' multidimensional analysis model revealed that besides the total ifosfamide dose and co-administration of other toxic drugs, polymorphic locus of GSTP1 gene may be one of the factors determining a higher toxicity of the cytostatic agent." | 1.33 | Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children. ( Misiura, K; Zielińska, E; Zubowska, M, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 7 (26.92) | 18.7374 |
1990's | 7 (26.92) | 18.2507 |
2000's | 4 (15.38) | 29.6817 |
2010's | 7 (26.92) | 24.3611 |
2020's | 1 (3.85) | 2.80 |
Authors | Studies |
---|---|
Gökçe, F | 1 |
Kaestli, A | 1 |
Lohasz, C | 1 |
de Geus, M | 1 |
Kaltenbach, HM | 1 |
Renggli, K | 1 |
Bornhauser, B | 1 |
Hierlemann, A | 1 |
Modena, M | 1 |
Teepen, JC | 1 |
van Leeuwen, FE | 1 |
Tissing, WJ | 1 |
van Dulmen-den Broeder, E | 1 |
van den Heuvel-Eibrink, MM | 1 |
van der Pal, HJ | 1 |
Loonen, JJ | 1 |
Bresters, D | 1 |
Versluys, B | 1 |
Neggers, SJCMM | 1 |
Jaspers, MWM | 1 |
Hauptmann, M | 1 |
van der Heiden-van der Loo, M | 1 |
Visser, O | 1 |
Kremer, LCM | 1 |
Ronckers, CM | 1 |
Opydo-Chanek, M | 1 |
Śladowska, K | 1 |
Blicharski, K | 1 |
Mikeš, J | 1 |
Fedoročko, P | 1 |
Niemeyer, U | 1 |
Mazur, L | 1 |
Rigaud, C | 1 |
Auperin, A | 1 |
Jourdain, A | 1 |
Haouy, S | 1 |
Couec, ML | 1 |
Aladjidi, N | 1 |
Gandemer, V | 1 |
Lambliotte, A | 1 |
Plat, G | 1 |
Landman-Parker, J | 1 |
Michon, J | 1 |
Leblanc, T | 1 |
Patte, C | 1 |
Minard-Colin, V | 1 |
Say, R | 1 |
Uzun, L | 1 |
Yazar, S | 1 |
Denizli, A | 1 |
Hür, D | 1 |
Yılmaz, F | 1 |
Ersöz, A | 1 |
Hoelzer, D | 1 |
Walewski, J | 1 |
Döhner, H | 1 |
Viardot, A | 1 |
Hiddemann, W | 2 |
Spiekermann, K | 1 |
Serve, H | 1 |
Dührsen, U | 1 |
Hüttmann, A | 1 |
Thiel, E | 1 |
Dengler, J | 1 |
Kneba, M | 1 |
Schaich, M | 1 |
Schmidt-Wolf, IG | 1 |
Beck, J | 1 |
Hertenstein, B | 1 |
Reichle, A | 1 |
Domanska-Czyz, K | 1 |
Fietkau, R | 1 |
Horst, HA | 1 |
Rieder, H | 1 |
Schwartz, S | 1 |
Burmeister, T | 1 |
Gökbuget, N | 1 |
Ramirez, MD | 1 |
Mertens, AC | 1 |
Esiashvili, N | 1 |
Meacham, LR | 1 |
Wasilewski-Masker, K | 1 |
Bruserud, O | 1 |
Reikvam, H | 1 |
Kittang, AO | 1 |
Ahmed, AB | 1 |
Tvedt, TH | 1 |
Sjo, M | 1 |
Hatfield, KJ | 1 |
Misiura, K | 2 |
Szymanowicz, D | 1 |
Kuśnierczyk, H | 1 |
Wietrzyk, J | 1 |
Opolski, A | 1 |
Oriol, A | 1 |
Ribera, JM | 1 |
Brunet, S | 1 |
del Potro, E | 1 |
Abella, E | 1 |
Esteve, J | 1 |
Zielińska, E | 1 |
Zubowska, M | 1 |
Moleti, ML | 1 |
Testi, AM | 1 |
Giona, F | 1 |
Malandruccolo, L | 1 |
Pescarmona, E | 1 |
Martino, P | 1 |
Paoloni, F | 1 |
Barberi, W | 1 |
Palumbo, G | 1 |
Mandelli, F | 1 |
Foa, R | 1 |
Gahrton, G | 1 |
Carter, SK | 1 |
Norberg, B | 1 |
Holm, J | 1 |
Winqvist, E | 1 |
Wahlin, A | 1 |
Hattori, M | 1 |
Tanaka, M | 1 |
Yamazaki, Y | 1 |
Nakahara, Y | 1 |
Tsushita, K | 1 |
Utumi, M | 1 |
Fields, KK | 1 |
Elfenbein, GJ | 1 |
Lazarus, HM | 1 |
Cooper, BW | 1 |
Perkins, JB | 1 |
Creger, RJ | 1 |
Ballester, OF | 1 |
Hiemenz, JH | 1 |
Janssen, WE | 1 |
Zorsky, PE | 1 |
Pratt, CB | 3 |
Kushner, BH | 1 |
Heller, G | 1 |
Cheung, NK | 1 |
Wollner, N | 1 |
Kramer, K | 1 |
Bajorin, D | 1 |
Polyak, T | 1 |
Meyers, PA | 1 |
Rodriguez, V | 1 |
McCredie, KB | 1 |
Keating, MJ | 1 |
Valdivieso, M | 1 |
Bodey, GP | 2 |
Freireich, EJ | 1 |
Büchner, T | 1 |
Urbanitz, D | 1 |
Kamanabroo, D | 1 |
Meister, R | 1 |
Balleisen, L | 1 |
Delvos, U | 1 |
Lagrèze, EM | 1 |
Schmitz-Huebner, U | 1 |
Schulte, H | 1 |
van de Loo, J | 1 |
Rentschler, RE | 1 |
Barlogie, B | 1 |
Johnston, DA | 1 |
Iwasaku-Fujimoto, M | 1 |
Fujiwara, F | 1 |
Todo, S | 1 |
Morioka, Y | 1 |
Imashuku, S | 1 |
Brade, WP | 1 |
Herdrich, K | 1 |
Varini, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7)[NCT00199082] | Phase 4 | 650 participants (Anticipated) | Interventional | 2002-07-31 | Completed | ||
Intensive Conditioning Regimen With Thiotepa Combined With Busulfan, Fludarabine and Cytarabine for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Myeloid Malignancies With Extramedullary Involvement[NCT06111612] | 50 participants (Anticipated) | Observational | 2024-01-01 | Not yet recruiting | |||
LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)[NCT00466258] | Phase 4 | 50 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
7 reviews available for ifosfamide and Leucocythaemia
Article | Year |
---|---|
High-dose etoposide in allogeneic stem cell transplantation.
Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chem | 2012 |
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinone | 1983 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto | 1996 |
Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Chil | 1992 |
Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Leukemia; Lymphoma; Neopl | 1990 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
9 trials available for ifosfamide and Leucocythaemia
Article | Year |
---|---|
Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Carbopl | 2019 |
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine- | 2014 |
Yield of Urinalysis Screening in Pediatric Cancer Survivors.
Topics: Adolescent; Adult; Child; Child, Preschool; Databases, Factual; Female; Follow-Up Studies; Glycosuri | 2016 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1995 |
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Res | 1998 |
Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment.
Topics: Acute Disease; Adolescent; Adult; Clinical Trials as Topic; Cyclophosphamide; Drug Resistance; Femal | 1978 |
Intensification of remission induction therapy for acute nonlymphocytic leukemia (ANLL). I. Response and toxicity in four different regimens.
Topics: Acute Disease; Age Factors; Cytarabine; Daunorubicin; Drug Therapy, Combination; Humans; Ifosfamide; | 1979 |
Ifosfamide--pharmacology, safety and therapeutic potential.
Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu | 1985 |
12 other studies available for ifosfamide and Leucocythaemia
Article | Year |
---|---|
Microphysiological Drug-Testing Platform for Identifying Responses to Prodrug Treatment in Primary Leukemia.
Topics: Child; Coculture Techniques; Humans; Ifosfamide; Leukemia; Liver; Prodrugs | 2023 |
Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy.
Topics: Adolescent; Adult; Adult Survivors of Child Adverse Events; Aged; Antineoplastic Agents; Bone Neopla | 2017 |
Comparison of
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Membrane; Cell Survival; Cyclopho | 2017 |
Bitargeting and ambushing nanotheranostics.
Topics: Antineoplastic Agents; Apoptosis; Drug Delivery Systems; HL-60 Cells; Humans; Ifosfamide; Leukemia; | 2014 |
Isophosphoramide mustard analogues as prodrugs for anticancer gene-directed enzyme-prodrug therapy (GDEPT).
Topics: Animals; Antineoplastic Agents; Carcinoma; Chromatography, High Pressure Liquid; Cytochrome P-450 En | 2002 |
Highly active antiretroviral therapy and outcome of AIDS-related Burkitt's lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ant | 2005 |
Role of GSTM1, GSTP1, and GSTT1 gene polymorphism in ifosfamide metabolism affecting neurotoxicity and nephrotoxicity in children.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Child; Child, Preschool; Cyclophosph | 2005 |
CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, P | 2007 |
Treatment of advanced bone marrow neoplasms with ifosfamide combinations.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphami | 1984 |
Detection of major and minor bcr/abl fusion gene transcripts in a patient with acute undifferentiated leukemia secondary to treatment with an alkylating agent.
Topics: Acute Disease; Alkylating Agents; Anemia, Sideroblastic; Base Sequence; Cell Transformation, Neoplas | 1995 |
In vivo perturbation of human marrow cell cycle progression by ifosfamide.
Topics: Bone Marrow; Cell Cycle; Cyclophosphamide; DNA, Neoplasm; Erythroblasts; Humans; Ifosfamide; Kinetic | 1978 |
[Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
Topics: Bone Neoplasms; Child; Cyclophosphamide; Cystitis; Female; Hematuria; Humans; Ifosfamide; Leukemia; | 1990 |